Slimane Allali, Pierre Lemaire, Ana-Claudia Couto-Silva, Géraldine Prété, Christine Trivin, Raja Brauner
Med Sci Monit 2011; 17(6): PH41-48
Background: There are no absolute criteria for identifying those girls with idiopathic central precocious puberty (CPP) who will benefit from gonadotropin-releasing hormone analog (GnRHa) treatment. Our objective was to predict at initial evaluation the differences between adult height (AH) and target height (TH) and (for untreated girls) the time between puberty onset and first menstruation.
Material/Methods: The 122 girls with CPP who reached their AH included 70 who were given GnRHa because their predicted AH was <155 cm (n=24), their luteinising hormone (LH)/follicle-stimulating hormone peaks (FSH) ratio was >0.66 (n=41) and/or their estradiol was >15 pg/ml (n=40). The other 52 were untreated because their predicted AH was >155 cm. Multiple linear regressions were performed on several subsets of variables.
Results: Treated: the difference between AH and TH (–0.6±5.4 cm) was predicted by (using SDS) =3.68 (height at initial evaluation – TH) – 1.94 (height at initial evaluation-predicted AH) – 4.23; R2=0.73. Untreated: the difference between AH and TH (1.7±4.3 cm) was predicted by =2.76 (height at initial evaluation – TH) – 3.68 LH/FSH peaks ratio – 3.49; R2=0.77. Time between puberty onset and first menstruation (years) was predicted by =12.2 – 1.06 age CPP – 0.4 (height at initial evaluation – TH); R2=0.75.
Conclusions: A greater difference between height at initial evaluation and TH (SDS) is associated with a greater AH in treated and untreated girls, as are smaller differences between height at initial evaluation and predicted AH in treated and lower LH/FSH peaks ratios in untreated girls.
Keywords: Menstruation - physiology, Puberty, Precocious - therapy, Humans, Female, Body Height - physiology, Adult